Spotlight Kratom Industry Dangers — While FDA Targets the Alternative, 7-OH

Spotlight Kratom Industry Dangers — While FDA Targets the Alternative, 7-OH 

SourceHART Supporter

Excerpt:

WASHINGTON, DC – Two major national news outlets — USA Today and the New York Post — published scathing new reports this week exposing the growing public health crisis fueled by kratom and its unregulated derivatives. Together, the stories reveal a disturbing pattern: while everyday Americans fall victim to addiction, withdrawal, and predatory marketing, federal officials are refusing to go after the actual source of danger, instead targeting 7- hydroxymitragynine (7-OH), an industry competitor that the FDA’s own databases have shown to have far fewer adverse events.

Facebook
Twitter
LinkedIn
WhatsApp
Email
Print
Scroll to Top